Product Reports Resources Pricing Login Book a demo

Caribou Biosciences

Biotech & Life Sciences · Berkeley, United States · Founded 2011 · IPO 2021

Biotechnology company focused on genome engineering and developing technology-based solutions for cells

Valuation $54M
Revenue $26M

Investors

29 investors on Caribou Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Series B+ 23 investors entered at this stage
F-Prime
Janus Henderson Investors
Tekla Capital Management
Farallon Capital Management
Avego Bioscience Capital
LifeSci Venture Partners
Avidity Partners
Monashee Investment Management
Pontifax AgTech
Ridgeback Capital
AbbVie
Mission Bay Capital
Adage Capital
Heritage Medical Systems
The Leukemia & Lymphoma Society
Point72 Ventures
Maverick Capital
Anterra Capital
University of California
Berkeley
PFM Health Sciences
Invus
Heritage Group

Global footprint

Where Caribou Biosciences has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
8.8K monthly visits
across markets
🇺🇸 United States80.7%
🇮🇳 India11.4%
🇯🇵 Japan8%
Top 3 markets shown

Talent graph

The shape of Caribou Biosciences's talent

Dealroom maps Caribou Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Caribou Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$98M patent portfolio · 33 active families

Estimated portfolio value
$98M
182.0% of market cap · 24.3× smaller than top peer Illumina ($2.4B)
33 active patent families
Where Caribou Biosciences innovates BioinformaticsCAR - Chimeric antigen receptorCRISPRCell biologyExpression cassette

Where Caribou Biosciences concentrates vs peers

Each axis is a top-10 topic across Caribou Biosciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Caribou Biosciences

An AI-synthesized read of the highest-engagement posts about Caribou Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Caribou Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.